Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets

Inclusion Criteria: * Study participants aged 18 to 60 years (inclusive of 18 and 60 years), both male and female * Body weight not less than 50 kg. Body Mass Index (BMI) = weight (kg) / height\^2 (m\^2). BMI must be within the range of 19 to 26 kg/m\^2 (inclusive of the limit values) * The study participant is able to communicate well with the research staff, fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial, and sign a written informed consent form * The study participant or their partner has no plans for pregnancy, sperm donation, or egg donation during the study period and for 3 months after drug administration, and must agree to use at least one acceptable effective contraceptive method * During the screening period: 110 mmHg ≤ seated systolic blood pressure (SBP) \< 140 mmHg, 65 mmHg ≤ seated diastolic blood pressure (DBP) \< 90 mmHg, and no orthostatic hypotension. Exclusion Criteria: * Those who smoked more than 5 cigarettes per day on average in the 3 months prior to the trial and are unable to quit smoking during the trial period. * Pregnant or breastfeeding women, or female study participants of childbearing potential with a positive blood pregnancy screening. * Known allergic reaction to angiotensin II receptor antagonists (such as sacubitril/valsartan sodium, alisartan ester, losartan, valsartan) and calcium channel blockers (such as nifedipine, amlodipine), or their excipients; or allergic constitution …